BXP
NEUTRALBeximco Pharma Provides Update on BSEC Order
The pharmaceutical company provides an update on the ongoing High Court hearing regarding the BSEC's proposed appointment of additional independent directors to the Board.
Beximco Pharmaceuticals Limited
35.00GBX
0.00%
Market Cap
165.06M
Volume
50k
173% of avg
P/E Ratio
0.04
EPS (TTM)
8.14
Beta
0.56
Day Range
0.00p - 0.00p
52 Week Range
0.00p35.00p41.00p
35.00p
Upcoming Events
29 July 2025
Expected Full Year Results 2024-25 (estimated)
High Impact Event
BXP
NEUTRALBeximco Pharma Requests Extension to Publish Q3 Results
The pharmaceutical company has requested an extension to publish its Q3 financial results due to an ongoing legal matter regarding the appointment of additional independent directors.
BXP
NEUTRALBeximco Pharma Denies Corruption Allegations, Provides Update on Regulatory Order
The pharmaceutical company denies allegations of corruption in Covid-19 vaccine procurement and provides an update on a regulatory order regarding its board of directors.
BXP
NEUTRALBeximco Pharma Faces Regulatory Uncertainty Over Board Appointments
The pharmaceutical company faces regulatory uncertainty over the proposed appointment of additional independent directors to its board, with a court decision expected by mid-March.
BXP
NEUTRALBeximco Pharma Announces Board Change
The pharmaceutical company has announced a change in its Board of Directors, with a new Non-Executive Director nominated by a major shareholder.
BXP
GOODBeximco Pharmaceuticals Reports Strong Half-Year Results with 17.5% Profit Growth
The generic drug manufacturer reported an 8.8% increase in net sales and a 17.5% rise in profit after tax for the half-year. Export sales surged by 31.6%, with expansion into new markets.
BXP
NEUTRALBeximco Pharma Faces Board Shake-Up as Regulator Seeks to Appoint New Directors
Pharmaceutical company faces potential Board shake-up as regulator seeks to appoint new directors
BXP
NEUTRALBeximco Pharmaceuticals Holds Annual General Meeting
The pharmaceutical company held its Annual General Meeting, approving a 40% cash dividend and a name change, but the announcement contains no major updates.
BXP
NEUTRALBeximco Pharma Announces AGM, Dividend and Name Change
Pharmaceutical company Beximco announces upcoming AGM and routine corporate updates.
BXP
NEUTRALBeximco Pharma Reports Modest Q1 Revenue Growth, Confident in Execution
Pharmaceutical company reports modest Q1 revenue growth, but remains confident in its business strategy.